Business, energy, technology, markets and global industry news from Business News Today

CD3 bispecific antibody

PharmaDeviceNews CD3 bispecific antibody
Representative image: Harbour BioMed’s FDA-cleared HBM7004 IND highlights the growing race to develop B7-H4xCD3 bispecific antibodies for advanced solid tumors, as biotech firms test whether next-generation immunotherapies can improve cancer treatment options beyond conventional approaches.
Pharma & Biotech

HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test

Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.

Read More